Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) EBITDA Margin (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of EBITDA Margin readings, the most recent being 803.49% for Q1 2026.

  • On a quarterly basis, EBITDA Margin fell 84221.0% to 803.49% in Q1 2026 year-over-year; TTM through Mar 2026 was 40.91%, a 3311.0% decrease, with the full-year FY2025 number at 27.06%, up 9313.0% from a year prior.
  • EBITDA Margin hit 803.49% in Q1 2026 for Atara Biotherapeutics, down from 213.61% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 38.72% in Q1 2025 to a low of 33339.37% in Q4 2022.
  • Median EBITDA Margin over the past 5 years was 169.08% (2025), compared with a mean of 3458.4%.
  • The widest YoY moves for EBITDA Margin: up 3210715bps in 2023, down -896302bps in 2023.
  • Atara Biotherapeutics' EBITDA Margin stood at 33339.37% in 2022, then surged by 96bps to 1232.22% in 2023, then surged by 97bps to 38.8% in 2024, then crashed by -451bps to 213.61% in 2025, then crashed by -276bps to 803.49% in 2026.
  • The last three reported values for EBITDA Margin were 803.49% (Q1 2026), 213.61% (Q4 2025), and 124.56% (Q3 2025) per Business Quant data.